Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

April 30th 2025

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29th 2025

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

April 29th 2025

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Dr Pavlick on RP1 Plus Nivolumab in PD-1 Inhibitor–Pretreated Melanoma

April 29th 2025

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses efficacy data with RP1 plus nivolumab in patients with melanoma who had progressed on PD-1–directed therapy.

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

April 28th 2025

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC

April 28th 2025

S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.

Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC

April 28th 2025

Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.

Dr Sekeres on Next Steps for Evaluating the Association Between Smoking and MDS

April 25th 2025

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Dr Cortese on Potential Mechanisms for Improving CLL Outcomes With Venetoclax

April 25th 2025

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

April 25th 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

Awareness Efforts Aim to Drive Earlier Esophageal Cancer Detection Amid Rising Incidence Rates

April 25th 2025

Nataliya Uboha, MD, PhD, highlights the importance of standard endoscopic procedures for the early detection of esophageal cancer.

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

April 24th 2025

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Dr McNall-Knapp on the Efficacy of MEK Inhibition in NF1-Associated PNs

April 24th 2025

Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.

Dr Oberstein on Clinical Applications for Oncodetect in MRD Detection in Solid Tumors

April 24th 2025

Paul E. Oberstein, MD, discusses the clinical applications of the Oncodetect test for molecular residual disease detection in patients with solid tumors.

Dr Ali on the Potential SOC Role of Palbociclib Plus Anti-HER2 and Endocrine Therapy in HER2+ Breast Cancer

April 24th 2025

Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.

Mirdametinib Use in NF1-Associated PNs Balances Efficacy and QOL Considerations

April 24th 2025

Rene Y. McNall-Knapp, MD, discusses the symptom management associated with mirdametinib and MEK inhibition in NF1-associated PNs.

Oncodetect MRD Test Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD

April 23rd 2025

Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.

Nivolumab/Ipilimumab Stands as the SOC for MSI-H/dMMR mCRC

April 23rd 2025

Heinz-Josef Lenz, MD, and Van Karlyle Morris, MD, discuss the significance of the FDA approval of nivolumab plus ipilimumab for MSI-H/dMMR mCRC.

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC

April 23rd 2025

Aiwu Ruth He, MD, PhD, discusses data from the CheckMate 9DW trial that supported the FDA approval of frontline nivolumab plus ipilimumab for advanced HCC.